[1]肖金平,付景秋,李小雷,等.参松养心胶囊治疗高血压并发阵发性房颤的临床疗效及安全性分析[J].西部中医药,2021,34(08):110-112.[doi:10.12174/j.issn.2096-9600.2021.08.24]
　XIAO Jinping,FU Jingqiu,LI Xiaolei,et al.Analysis of the Safety and Clinical Effects of Shensong Yangxin Capsules in Treating Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Western Journal of Traditional Chinese Medicine,2021,34(08):110-112.[doi:10.12174/j.issn.2096-9600.2021.08.24]
点击复制

参松养心胶囊治疗高血压并发阵发性房颤的临床疗效及安全性分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年08期
页码:
110-112
栏目:
出版日期:
2021-08-15

文章信息/Info

Title:
Analysis of the Safety and Clinical Effects of Shensong Yangxin Capsules in Treating Hypertension Complicated with Paroxysmal Atrial Fibrillation
作者:
肖金平, 付景秋, 李小雷, 纪道兵, 陈俊
湖北医药学院附属国药东风总医院，湖北 十堰 442008
Author(s):
XIAO Jinping, FU Jingqiu, LI Xiaolei, JI Daobing, CHEN Jun
Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan 442008, China
关键词:
高血压并发阵发性房颤; 参松养心胶囊; 临床疗效; 安全性
Keywords:
hypertension complicated with paroxysmal atrial fibrillation; capsules; clinical effects; safety
分类号:
R541.3
DOI:
10.12174/j.issn.2096-9600.2021.08.24
摘要:
目的观察中药参松养心胶囊对高血压并发阵发性房颤的临床疗效及安全性。 方法选择高血压并发阵发性房颤患者110例，随机分为观察组和对照组，每组55例。两组均采用常规手段治疗，观察组在此基础上加用参松养心胶囊治疗。评价两组患者生活质量评分、运动耐量试验评分、临床疗效及不良反应发生情况。 结果观察组治疗3、6个月后阵发性房颤1周内发生次数明显少于对照组（P＜0.05）；观察组治疗后生活质量评分和6 min运动耐力评分均高于对照组（P＜0.05）；观察组总有效率［90.91%（50/55）］高于对照组［76.36%（42/55）］（P＜0.05）；两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。 结论参松养心胶囊治疗高血压并发阵发性房颤，可提高患者生活质量、运动耐量评分及总有效率，且无明显不良反应。
Abstract:
ObjectiveTo explore clinical effects and the safety of Shensong Yangxin capsules in treating hypertension complicated with paroxysmal atrial fibrillation. MethodsAll 110 hypertension patients complicated with paroxysmal atrial fibrillation were chosen and randomized into the control group and the observation group, 55 cases in each group. Both groups adopted conventional therapy, and the observation group took Shensong Yangxin capsules orally. To assess the scores of quality of life and exercise tolerance test, clinical effects and the conditions of adverse reaction between both groups. ResultsThe frequency of paroxysmal atrial fibrillation within one week of the observation group after treating for three and six months was lower than that of the control group notably (P<0.05); the observation group was higher than the control group in the scores of quality of life and six minutes exercise tolerance test (P<0.05); total effective rate of the observation group was 90.91% (50/55), higher than 76.36% (42/55) of the control group (P<0.05); the difference had no statistical meaning in the incidence of adverse reaction between both groups (P>0.05). ConclusionShensong Yangxin capsules in treating hypertension complicated with paroxysmal atrial fibrillation could lift quality of life and the scores of exercise tolerance test, raise therapeutic effective rate without notable adverse reaction.

相似文献/References:

[1]宋吉法.ACEI、ARB联合参松养心胶囊治疗慢性心力衰竭42例疗效观察[J].西部中医药,2012,25(07):63.
　SONG Ji-fa.Observation on Clinical Effects of ACEI and ARB Combined with ShenSong YangXin Capsule in Treating 42 Cases of Congestive Heart Failure[J].Western Journal of Traditional Chinese Medicine,2012,25(08):63.
[2]刘雅琴,李淑玲,祁泉.参松养心胶囊治疗老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床观察[J].西部中医药,2024,37(04):139.[doi:10.12174/j.issn.2096-9600.2024.04.29]
　LIU Yaqin,LI Shuling,QI Quan.Clinical Observation of Shensong Yangxin Capsules in the Treatment of the Elderly with CHD-induced Premature Ventricular Contraction of Qi-yin Deficiency Pattern and Stagnation of Cardiac Collateral Pattern[J].Western Journal of Traditional Chinese Medicine,2024,37(08):139.[doi:10.12174/j.issn.2096-9600.2024.04.29]

备注/Memo

备注/Memo:
肖金平（1988—），男，硕士学位，主治医师。研究方向：心脏电生理学。2016年湖北省科技计划项目（2016CFB529）。
更新日期/Last Update: 2021-08-15